%A WU Zheng-Qi-；Zhang-Zhi-Yi-；Wang-Hui-Juan-；Liu-Xiao-Jun %T Research progress of three antiangiogenic agents in the treatment of advanced colorectal cancer %0 Journal Article %D 2015 %J Journal of International Oncology %R 10.3760/cma.j.issn.1673-422X.2015.04.017 %P 301-304 %V 42 %N 4 %U {https://gjzlx.sdfmu.edu.cn/CN/abstract/article_9651.shtml} %8 2015-04-08 %X Angiogenesis plays a vital role in carcinogenesis and development of colorectal cancer. Treatment targeting VEGF signaling pathway acquires important survival prolong for advanced colorectal cancer patients. For advanced colorectal cancer patients, bevacizumab could furtherly prolongs survival time in the setting of first line, second line and continuing therapy after firstprogression therapy combined with chemotherapy. Aflibercept used in combination with irinotecancontaining regimen improves the survival of advanced colorectal cancer patients in secondline setting. Regorafenib also improves the survival of advanced colorectal cancer patients who have progressed after all line treatment. Considering these suivival benefit and their favorable safety, antiangiogenic agents should be taken into all lines of therapy in the management of advanced colorectal cancer.